During the last session, Fulcrum Therapeutics Inc (NASDAQ:FULC)’s traded shares were 0.69 million, with the beta value of the company hitting 2.48. At the end of the trading day, the stock’s price was $7.83, reflecting an intraday loss of -2.25% or -$0.18. The 52-week high for the FULC share is $10.13, that puts it down -29.37 from that peak though still a striking 70.37% gain since the share price plummeted to a 52-week low of $2.32. The company’s market capitalization is $422.65M, and the average intraday trading volume over the past 10 days was 0.75 million shares, and the average trade volume was 626.75K shares over the past three months.
Fulcrum Therapeutics Inc (FULC) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.00. FULC has a Sell rating from 0 analyst(s) out of 13 analysts who have looked at this stock. 4 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 9 recommend a Buy rating for it.
Fulcrum Therapeutics Inc (NASDAQ:FULC) trade information
Fulcrum Therapeutics Inc (FULC) registered a -2.25% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -2.25% in intraday trading to $7.83, hitting a weekly high. The stock’s 5-day price performance is 13.15%, and it has moved by 13.48% in 30 days. Based on these gigs, the overall price performance for the year is 66.60%. The short interest in Fulcrum Therapeutics Inc (NASDAQ:FULC) is 5.82 million shares and it means that shorts have 10.67 day(s) to cover.
The consensus price target of analysts on Wall Street is $10.5, which implies an increase of 25.43% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $9 and $12 respectively. As a result, FULC is trading at a discount of -53.26% off the target high and -14.94% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 54.59%. While earnings are projected to return -616.41% in 2025.
FULC Dividends
Fulcrum Therapeutics Inc is due to release its next quarterly earnings on 2025-May-01. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Fulcrum Therapeutics Inc (NASDAQ:FULC)’s Major holders
Fulcrum Therapeutics Inc insiders own 1.82% of total outstanding shares while institutional holders control 96.20%, with the float percentage being 97.98%. RA CAPITAL MANAGEMENT, L.P. is the largest shareholder of the company, while 159.0 institutions own stock in it. As of 2024-06-30, the company held over 11.61 million shares (or 18.6636% of all shares), a total value of $71.98 million in shares.
The next largest institutional holding, with 5.85 million shares, is of RTW INVESTMENTS, LP’s that is approximately 9.3979% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $36.24 million.
Also, the Mutual Funds coming in first place with the largest holdings of Fulcrum Therapeutics Inc (FULC) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . Data provided on Mar 31, 2025 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 1.85 shares. This amounts to just over 3.43 percent of the company’s overall shares, with a $14.5 million market value. The same data shows that the other fund manager holds slightly less at 1.4, or about 2.59% of the stock, which is worth about $10.94 million.
